HEALTH● LOW1h ago · Sep 17, 2026, 5:08 PM
Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?
Yahoo Finance · global
Takeda Pharmaceutical has received priority review for Zasocitinib, a potential treatment for psoriasis. This development could lead to a new therapeutic option for the condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH23m agoWHO urges safer care for people living with noncommunicable diseasesPremium TimesHEALTH31m agoAU’s free Ayurvedic medical camp benefits 185 patientsThe HinduHEALTH1h agoThe misdirected narrative around Nigeria’s HIV response: Are we ready to change it?, By Adaeze OrehPremium TimesHEALTH1h agoChile First in South America to Eliminate Dog-Transmitted RabiesHuman Progress